In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of ...

Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.’s HPV vaccine ...

Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...

Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to ...

Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a ...

Amgen, LeBron James and world’s top-subscribed YouTuber MrBeast may sound like a Mad Lib of unrelated influences, but the ...

Amylyx Pharmaceuticals is helping patients follow the clues to uncover the mystery of rare weight-loss surgery complication post-bariatric hypoglycemia (PBH) with the launch of a new patient education ...

With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is once again positioned for a “growth story,” CEO Chris Viehbacher said ...

Regeneron’s cut from the Dupixent sales boom was $2.11 billion in the quarter, which topped analysts’ consensus by $358 ...

The three-year initiative is designed to generate 1.9 billion pound sterling ($2.5 billion) in annual cost savings by 2029, against 2.4 billion pound sterling in total one-time costs.  The cost ...

The FDA has rebuked Viatris for a direct-to-consumer (DTC) video that allegedly misled viewers about a cystic fibrosis ...

Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. | Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. Merck briefly posted—and then quickly ...